GILD Gilead Sciences Inc
Company Analysis
Latest News
Gilead and Merck Advance First Once-Weekly HIV Pill After Successful Trials
Gilead Sciences and Merck announced successful Phase 3 clinical trial results on June 8. The investigational once-weekly oral HIV treatment met its primary...
Gilead’s Livdelzi Hits Phase 3 Goal, Normalizing Key Liver Disease Marker
Gilead Sciences reported positive Phase 3 IDEAL study results for Livdelzi (seladelpar) in treating primary biliary cholangitis (PBC). The trial met its...
WHO Recommends Gilead's Remdesivir for Ebola Outbreak Trials
The World Health Organization (WHO) recommends prioritizing Gilead Sciences' antiviral drug remdesivir for clinical trials. These trials target an Ebola...
Zacks Research Sharply Cuts Q2 2026 Earnings Estimate for Gilead Sciences
Zacks Research lowered its second-quarter 2026 earnings per share (EPS) estimates for Gilead Sciences (NASDAQ:GILD). The firm now forecasts a Q2 EPS of...
Gilead Shares Climb 3% Following Landmark FDA Hepatitis Drug Approval
The FDA granted accelerated approval to Gilead Sciences’ Hepcludex (bulevirtide-gmod). Hepcludex is the first and only U.S.-approved therapy for adults with...
Gilead secures Hepcludex approval, first US hepatitis delta treatment
Gilead Sciences received accelerated FDA approval for Hepcludex on May 24, 2026. Hepcludex is the first and only treatment for chronic hepatitis delta virus in...
Gilead's first quarter 2026 revenue of $7.0B beat estimates, driven by 10% growth in its HIV franchise.
Gilead reported first quarter revenue of $7.0 billion and non-GAAP EPS of $2.03, beating analyst estimates. Results were driven by strong growth in the HIV and...
Gilead Sciences Inc Q1 2026 Earnings Preview: What Analysts Expect on May 07, 2026
Gilead Sciences is expected to report Q1 2026 revenue of $6.89 billion and EPS of $1.89, with its current stock price of $132.69 trading roughly 16% below the...